Skip to main content
. 2005 May 19;7(4):R535–R540. doi: 10.1186/bcr1035

Table 1.

Characteristics of 1316 users and 2839 nonusers of hormone therapy

Study Treatment n Mean age (years) Stage Nodal status ER status PgR status Mean DFI before HT (months) Estrogen alone (%) Mean duration of HT (months) Mean follow-up after HT (months) Recurrences (n) Deaths, all cause (n) Deaths, primary tumor (n)
Randomized trials
Marsden et al. (2000; n = 100) [20] HT 51a 58b NR NR NR NR 40b NR 6 NR 2 NR NR
No HT 49a 55b NR NR NR NR 36b NR 1 NR NR
Holmberg et al. (2004; n = 345) [9] HT 174 55.5 NR 25.9% (38) positive 86 positivec NR 31.2b NR 24 25.2b 26 5 3
No HT 171 55.0 NR 21.4% (31) positive 73 positivec NR 32.4b 25.2b 7 4 4
Observational studies
Ursic-Vrscaj and Bebar (1999; n = 63) [27] HT 21d 47b 1 G1
10 G2
7 G3		 14 negative, 7 positive 5 positive, 16 negative 8 positive, 13 negative 62 4.8 28 38g 4 0g 0
No HT 42d 48.2 7 G1
17 G2
11 G3		 28 negative 14 positive 18 positive, 22 negative 22 positive, 18 negative NR 38g 5 1g 1
DiSaia et al. (2000; n = 487) [22] HT 125 55.7 17 DCIS
52 stage I
27 stage II
10 stage III
1 stage IV		 NR NR NR 46b 28 22b 92.1g NR 4g NR
No HT 362 55.9 NR NR NR NR NR 90.6g NR 57g NR
O'Meara et al. (2001; n = 869) [36] HT 174d 63.6e 91 stage I
51 stage II
20 stage I/II
10 stage III
2 stage II/III		 128 negative, 31 positive 84 positive, 39 negative 71 positive, 45 negative 47.7e 79 15b 44.4b,f 16 17 5
No HT 695d 63.6e 403 stage I
246 stage II
3 stage I/II
42 stage III
1 stage II/III		 470 negative, 175 positive 409 positive, 137 negative 311 positive, 206 negative 47.7e 44.4b,f 101 115 59
Beckmann et al. (2001; n = 185) [24] HT 64 NA 37 T1
19 T2
8 T3/4		 44 negative, 20 positive 31 positive, 33 negative 34 positive, 30 negative 0 NA 33b 37b 6 4 NR
No HT 121 NA 62 T1
42 T2
17 T3/4		 76 negative, 45 positive 48 positive, 73 negative 48 positive, 73 negative 0 42b 17 15 NR
Marttunnen et al. (2001; n = 131) [26] HT 88 53.4 3 DCIS
67 T1
17 T2
1 T3		 72 negative, 10 positive 57 positive, 15 negative 54 positiveg, 13 negativeg 50.4 38.6 30 30 7 2 2
No HT 43 52.8 1 DCIS
29 T1
11 T2
2 T3		 30 negative, 13 positive 29 positive, 9 negative 30 positiveg, 7 negativeg 50.4 31.2 5 3 3
Durna et al. (2002; n = 1122) [23] HT 286 56.8b 180 stage I
64 stage II
22 stage III/IV		 NA NR NR 12b 5.9 21b 69.6b 44 16 13
No HT 836 64.7b 470 stage I
191 stage II
120 stage III/IV		 NA NR NR NR 61.2b 247 199 122
Vassilopoulou-Sellin et al. (2002; n = 299) [21] HT 56h 56b 9 <1 cm
30 1–2.5 cm
15 >2.5 cm		 35 negative, 13 1–3, 6 >3 37 negative NR 105.6 100 30 >5 years, 20 2–5 years, 6 2 years 71 2 1 0
No HT 243h 53b 38 <1 cm
134 1–2.5 cm
67 >2.5 cm		 133 negative, 70 1–3, 33 >3 164 negative NR 99.6 NR 33 2 1
Decker et al. (2003; n = 554) [25] HT 277 57.4b 84 DCIS
124 stage I
47 stage IIA
19 stage IIB
3 stage IIIA		 NR 100 positive, 54 negative 63 positive, 46 negative 43.3 48.7 44.4 49.7 30 7 5
No HT 277 59.0b 84 DCIS
124 stage I
47 stage IIA
19 stage IIB
3 stage IIIA		 NR 121 positive, 35 negative 73 positive, 42 negative NR 45.6 35 17 9
Summary
Randomized trials HT 225 56.07 38 positive 86 positive 33.19 19.92 25.20 28 5 3
No HT 220 55.00 31 positive 73 positive 33.20 25.20 8 4 4
Observational studies HT 1091 56.98 293 negative, 87 positive 277 positive, 194 negative 230 positive, 147 negative 37.70 40.4 28.02 57.46 109 51 25
No HT 2619 60.87 737 negative, 350 positive 625 positive, 440 negative 484 positive, 346 negative 54.01 57.02 443 409 195
All combined HT 1316 56.82 293 negative, 125 positive 363 positive, 194 negative 230 positive, 147 negative 36.93 40.4 26.58 53.03 137 56 28
No HT 2839 60.39 737 negative, 381 positive 698 positive, 440 negative 484 positive, 346 negative 50.55 54.88 451 413 199

aExcluding stage III/IV patients. bMedian value. cRefers to hormone receptor status; specific data concerning estrogen receptor (ER) and progesterone receptor (PgR) status were not reported. dExcluding patients with ductal carcinoma in situ (DCIS). eWeighted mean. fFor recurrence only; follow-up for mortality was 55.2 months. gPersonal communication. hExcluding DCIS, stages III and IV, and ER-positive patients. DFI, disease-free interval; HT, hormone therapy; NA, not able to calculate; NR, not reported.